Visura Technologies, a medical device company based in Minneapolis, has introduced the TEECAD mini, the latest advancement in transesophageal echocardiography (TEE) imaging technology. Building upon the success of their FDA-cleared TEECAD System, Visura aims to enhance this unique technology to work with smaller probes. This effort is specifically geared towards adult patients with anatomical needs that are not adequately met by standard TEE probe sizes. At the upcoming American Society of Echocardiography (ASE) 2024, Visura will seek input from key opinion leaders and showcase the benefits of the TEECAD System at the TEECAD Innovation Station.
The launch of the TEECAD mini program signifies a significant milestone for Visura, following an 85% increase in evaluations at major medical centers and the growth of their clinical and commercialization teams. Dr. David Marmor, the founder and chief medical officer of Visura, underscored the lack of substantial updates in TEE probe technology since the 1970s and emphasized the critical advancement represented by TEECAD. Clinical data, presented by Dr. Sunil Mankad from Mayo Clinic at last year’s ASE meeting, illustrated the safety and efficacy of TEECAD in esophageal imaging, showing reduced probe placement time and increased first-pass intubation success rates without any adverse events. Visura’s commitment to innovation and expanding their product portfolio aligns with market demands and enhances patient care.
To access more exclusive content, including this article, please consider subscribing. Subscribe now for more information on this topic and to stay updated on the latest industry developments.